for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Assembly Biosciences Inc

ASMB.OQ

Latest Trade

16.71USD

Change

-0.31(-1.82%)

Volume

77,126

Today's Range

16.30

 - 

17.11

52 Week Range

8.16

 - 

25.07

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Assembly Biosciences Posts Q3 Loss Per Share Of $0.96

Nov 7 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q3 LOSS PER SHARE $0.96.Q3 EARNINGS PER SHARE ESTIMATE $-0.93 -- REFINITIV IBES DATA.ASSEMBLY BIOSCIENCES - CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES WERE ABOUT $156.9 MILLION AS OF SEPTEMBER 30 VERSUS ABOUT $173.8 MILLION AS OF JUNE 30, 2019.QUARTER-END CASH POSITION IS PROJECTED TO FUND OPERATIONS INTO 2021.ASSEMBLY BIOSCIENCES - REVENUE FROM COLLABORATIVE RESEARCH WERE ABOUT $4.2 MILLION FOR 3 MONTHS ENDED SEPT 30, COMPARED TO $4.3 MILLION FOR SAME PERIOD IN 2018.

Assembly Biosciences Announces Appointment Of John Mchutchison As President And Chief Executive Officer

Aug 7 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES ANNOUNCES APPOINTMENT OF JOHN MCHUTCHISON, AO, MD, AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.ASSEMBLY BIOSCIENCES - JOHN MCHUTCHISON SUCCEEDS DEREK SMALL, CO-FOUNDER OF CO, WHO WILL CONTINUE AS A BOARD MEMBER AND SENIOR ADVISOR.ASSEMBLY BIOSCIENCES INC - MCHUTCHISON MOST RECENTLY SERVED AS CHIEF SCIENTIFIC OFFICER AND HEAD OF RESEARCH AND DEVELOPMENT AT GILEAD SCIENCES.

Assembly Biosciences Q2 Loss Per Share $0.72

Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q2 LOSS PER SHARE $0.72.Q2 EARNINGS PER SHARE ESTIMATE $-1.15 -- REFINITIV IBES DATA.QTRLY REVENUES FROM COLLABORATIVE RESEARCH WERE APPROXIMATELY $3.1 MILLION VERSUS $3.2 MILLION.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE APPROXIMATELY $173.8 MILLION AS OF JUNE 30, 2019.QUARTER-END CASH POSITION IS PROJECTED TO FUND OPERATIONS INTO 2021.

Assembly Biosciences Q1 Loss Per Share $1.05

May 9 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 LOSS PER SHARE $1.05.Q1 EARNINGS PER SHARE ESTIMATE $-1.04 -- REFINITIV IBES DATA.

Assembly Biosciences Announces Changes To Senior Leadership Team

May 2 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES ANNOUNCES CHANGES TO SENIOR LEADERSHIP TEAM.ASSEMBLY BIOSCIENCES INC - DEPARTURE OF GRAHAM COOPER, CHIEF FINANCIAL OFFICER AND CHIEF OPERATING OFFICER.ASSEMBLY BIOSCIENCES INC - GRAHAM COOPER IS LEAVING TO PURSUE OTHER INTERESTS.ASSEMBLY BIOSCIENCES - INITIATED SEARCH FOR NEW CFO, MICHAEL SAMAR, APPOINTED AS PRINCIPAL ACCOUNTING OFFICER,ASSUMED SOME OF COOPER'S RESPONSIBILITIES.

Armistice Capital Llc Reports A 6.6 Percent Passive Stake In Assembly Biosciences Inc As Of April 15, 2019

April 25 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ARMISTICE CAPITAL LLC REPORTS A 6.6 PERCENT PASSIVE STAKE IN ASSEMBLY BIOSCIENCES INC AS OF APRIL 15, 2019 - SEC FILING.

Assembly Biosciences Says ABI-H3733 Demonstrated Enhanced Potency In Preclinical Studies

April 11 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES INC - ABI-H3733 DEMONSTRATED ENHANCED POTENCY IN PRECLINICAL STUDIES.ASSEMBLY BIOSCIENCES INC - PHASE 1A STUDY OF ABI-H2158 DEMONSTRATED SAFETY, TOLERABILITY AND ACHIEVEMENT OF TARGET LIVER CONCENTRATIONS.ASSEMBLY BIOSCIENCES INC - ABI-H3733 DEMONSTRATED ENHANCED POTENCY IN PRECLINICAL STUDIES.

Assembly Biosciences Reports Fourth Quarter And Year End 2018 Financial Results

Feb 28 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.03.Q4 EARNINGS PER SHARE ESTIMATE $-0.91 -- REFINITIV IBES DATA.REVENUES CONSISTING OF REVENUE FROM COLLABORATIVE RESEARCH WERE ABOUT $3.7 MILLION FOR 3-MONTHS ENDED DEC 31, 2018 VERSUS $3.3 MILLION.Q4 REVENUE VIEW $4.2 MILLION -- REFINITIV IBES DATA.

Assembly Biosciences Announces Completion Of Enrollment In Two Phase 2A Studies

Jan 7 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT IN TWO PHASE 2A STUDIES WITH ABI-H0731 FOR CHRONIC HEPATITIS B VIRUS.ASSEMBLY BIOSCIENCES INC - ANTICIPATES REPORTING INTERIM RESULTS FROM BOTH STUDIES DURING Q2 OF 2019.ASSEMBLY BIOSCIENCES INC - DATA FROM ABI-2158 STUDY IS EXPECTED TO BE AVAILABLE IN FIRST HALF OF 2019.ASSEMBLY BIOSCIENCES INC - PLANNING TO ADVANCE ITS THIRD CORE INHIBITOR, ABI-H3733, INTO CLINICAL TRIALS IN 2019.

Assembly Biosciences Q3 Loss Per Share $0.87

Nov 8 (Reuters) - Assembly Biosciences Inc <ASMB.O>::ASSEMBLY BIOSCIENCES ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES HBV PROGRAM UPDATE.Q3 LOSS PER SHARE $0.87.Q3 EARNINGS PER SHARE VIEW $-1.03 -- THOMSON REUTERS I/B/E/S.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up